DCAL Q3 FY26 Unaudited Results: Consolidated Net Loss of ₹12.97 Crore
Dishman Carbogen Amcis Limited reported a consolidated net loss of ₹12.97 crore for Q3 FY26, with total income at ₹719.80 crore. Standalone results showed a net loss of ₹23.13 crore. The company's debt-equity ratio was 0.43 consolidated and 0.17 standalone. Goodwill amortization was revised to 99 years.
The net loss in the current quarter, while significant, is offset by a profit in the nine-month period, and the company has a substantial net worth. The revision in goodwill amortization is a long-term accounting change that might not have immediate operational impact.
The company reported a net loss in the current quarter's consolidated results, which is a negative development compared to the profit in the same quarter last year. The standalone results also showed an increased net loss.
Dishman Carbogen Amcis Limited (DCAL) announced its un-audited financial results for the third quarter and nine months ended December 31, 2025, following a Board of Directors meeting held on February 3, 2026. The company reported a consolidated net loss of ₹12.97 crore for the third quarter, a significant shift from a profit of ₹4.63 crore in the same period last year. Total income from operations for the quarter stood at ₹719.80 crore, an increase from ₹682.34 crore in the prior year's third quarter. The nine-month period ended December 31, 2025, also showed a consolidated net profit of ₹65.27 crore, compared to a loss of ₹39.85 crore in the corresponding period of the previous year. For the standalone results, the company registered a net loss of ₹23.13 crore for the third quarter ended December 31, 2025, an increase from a loss of ₹13.28 crore in the third quarter of the previous year. The nine-month standalone period ended December 31, 2025, reported a net loss of ₹34.06 crore, compared to a loss of ₹2.50 crore in the same period last year. The company also provided additional information regarding its financial ratios and debt-equity position, noting a debt-equity ratio of 0.43 for the consolidated results and 0.17 for standalone results as of December 31, 2025. A detailed note on the accounting treatment of goodwill arising from the amalgamation of Dishman Pharmaceuticals and Chemical Limited and Dishman Care Limited was also provided, with the Board deciding to amortize the goodwill over 99 years from January 1, 2015, prospectively from April 1, 2024.
What to do with a filing like this
Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.